Jonathan Covey
Psychiatry · Colorado Springs, CONPI 1639105638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 24.6% of the total. 2025 is the largest year on record at $2,393, 2.2 times the $1,065 reported in 2019. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $30.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$806
- Neurocrine Biosciences, Inc.$557
- Teva Pharmaceuticals USA, Inc.$516
- Sunovion Pharmaceuticals Inc.$452
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,76798%
- Education$1792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,958 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $1,713 |
| Alkermes, Inc. | 25 | $806 |
| Neurocrine Biosciences, Inc. | 17 | $557 |
| Teva Pharmaceuticals USA, Inc. | 9 | $516 |
| Sunovion Pharmaceuticals Inc. | 19 | $452 |
| E.r. Squibb & Sons, L.L.C. | 6 | $337 |
| Vanda Pharmaceuticals Inc. | 5 | $292 |
| Idorsia Pharmaceuticals US Inc | 10 | $253 |
| Eisai Inc. | 8 | $230 |
| Harmony Biosciences LLC | 3 | $192 |
| Axsome Therapeutics, Inc. | 2 | $150 |
| Johnson & Johnson | 2 | $123 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Merck | 4 | $61 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Bausch Health US, LLC | 2 | $35 |
| Sage Therapeutics, LLC | 1 | $30 |
| Almatica Pharma LLC | 1 | $26 |
| Adlon Therapeutics L.p. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,945 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $108,143 |
| CaplytaLumateperone Tosylate | 14 | $26,988 |
| VraylarCariprazine Hcl | 13 | $18,336 |
| LexaproEscitalopram Oxalate | 12 | $5,493 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $1,455 |
| Buspirone Hcl | 21 | $1,073 |
| Trazodone Hcl | 21 | $768 |
| Oxcarbazepine | 11 | $722 |
| Lamotrigine | 19 | $605 |
| Clonazepam | 14 | $576 |
| Zolpidem Tartrate | 50 | $574 |
| Eszopiclone | 19 | $526 |
| Duloxetine Hcl | 17 | $523 |
| Zaleplon | 12 | $493 |
| Mirtazapine | 12 | $421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $557 | $108,14313 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,713 | $26,98814 claims |
| AbbVieVraylar, Lexapro | $1,958 | $23,82925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Colorado Springs
- Kwang-Soo ParkColorado Springs$3K
- Kevin SnyderColorado Springs$3K
- Frederick MichelColorado Springs$3K
- Kevin BatterbeeColorado Springs$3K
- Peter MarlinColorado Springs$2K
- Ian GeisColorado Springs$2K
- Monica NicholsColorado Springs$2K
- Kevin KilimannColorado Springs$2K
- Brandon BakerColorado Springs$2K
- John HardyPueblo$828K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.